News ArticleGlobal Health Limited Revenue Grows 33.6% to INR 14,690 Million in Q2 FY2027; Approves 500-Bed Ghaziā Hospital
Operating EBITDA rises 60.2% to INR 3,701 million with occupancy reaching 67%; Board approves new super-specialty hospital development
Global Health Limited, operating under NSE: Medanta and BSE: 543654, announced a 33.6% year-on-year rise in Q2 FY2027 revenue to INR 14,690 million and a 60.2% jump in operating EBITDA to INR 3,701 million. The company added 74 beds this quarter, with an occupancy increase to 67%, and approved a new 500-bed super-specialty hospital project in Ghaziā at an estimated capex of INR 9,970 million.
Global Health Limited
General / Other
Global Health Limited reported strong financial performance for the quarter ended September 30, 2026, with revenue from operations rising 33.6% year-over-year to INR 14,690 million and operating EBITDA increasing by 60.2% to INR 3,701 million. The company expanded its bed capacity by 74 beds this quarter and approved constructing a new 500-bed super-specialty hospital in Ghaziā.
The quarter saw revenue growth driven by increased patient volumes and bed capacity expansion across Medanta’s hospital network, with total operational beds reaching 3,115 versus 2,658 in the prior year quarter.
The company’s operating EBITDA margin improved by 418 basis points to 25.2% in Q2 FY2027 compared to Q2 FY2026.
Profit after tax rose 38.3% year-on-year to INR 2,191 million with PAT margins at 14.9%.
Key additions during the quarter included 49 beds in Noida and 25 beds in Lucknow, with the Noida facility achieving EBITDA breakeven in Q2 FY2027.
Medanta’s board approved the development of a 500-bed super-specialty hospital in Ghaziā, with an estimated capital expenditure of approximately INR 9,970 million. The land for this project was acquired for INR 1,658.2 million in September 2026 through e-auction.
Highlights
- Q2 FY2027 revenue reached INR 14,690 million, a 33.6% increase year-over-year.
- Operating EBITDA grew 60.2% to INR 3,701 million with a margin of 25.2%.
- Total operational beds rose by approximately 17.2% year-over-year to 3,115 beds.
- Occupancy increased by 283 basis points to 67% in Q2 FY2027.
- Profit after tax improved 38.3% year-over-year to INR 2,191 million.
- Noida hospital achieved EBITDA breakeven within one year of opening with Q2 FY2027 EBITDA of INR 86 million from INR loss of INR 199 million in prior year quarter.
Key Data Snapshot
What happened
- Global Health Limited announced its second quarter and half year financial results ending September 30, 2026.
- The company reported a 33.6% year-on-year increase in revenue to INR 14,690 million in Q2 FY2027.
- Operating EBITDA rose by 60.2% to INR 3,701 million, with margins improving to 25.2%.
- Profit after tax grew 38.3% year-over-year to INR 2,191 million.
- The board approved a 500-bed super-specialty hospital project in Ghaziā following acquisition of a 2.61-acre land parcel through e-auction.
Key details
- Medanta added 74 new beds in Q2 FY2027: 49 in Noida and 25 in Lucknow, increasing operational beds to 3,115.
- Occupancy rates increased by 283 basis points to 67%.
- The Noida hospital achieved EBITDA breakeven in Q2 FY2027 within one year of operations.
- International patient revenue grew by 30.3% year-on-year to INR 993 million.
- Average revenue per patient increased slightly to INR 2.06 lakh.
- Medanta plans over 3,450 beds addition across six greenfield projects over upcoming years.
- Net cash surplus increased to INR 7,815 million as of September 30, 2026.
Strategic context
- The new Ghaziā hospital is positioned in a strong demand market for tertiary care.
- Estimated capital expenditure for the hospital is approximately INR 9,970 million.
- The company continues to expand capacity and clinical capabilities to meet growing healthcare needs in North and East India.
- Focus on disciplined, quality-led expansion supported by a strong balance sheet and cash flow generation.
Highlights
- Q2 FY2027 revenue reached INR 14,690 million, a 33.6% increase year-over-year.
- Operating EBITDA grew 60.2% to INR 3,701 million with a margin of 25.2%.
- Total operational beds rose by approximately 17.2% year-over-year to 3,115 beds.
- Occupancy increased by 283 basis points to 67% in Q2 FY2027.
- Profit after tax improved 38.3% year-over-year to INR 2,191 million.
- Noida hospital achieved EBITDA breakeven within one year of opening with Q2 FY2027 EBITDA of INR 86 million from INR loss of INR 199 million in prior year quarter.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
